Patent assignee · BE · COMPANY

Ogeda SA

22Patents
22Active
22Granted
49Portfolio score

Filing activity: Jun 18, 2012 → Oct 8, 2020

Most-cited patents

PatentTitleAreaCited byStatus
US9987274B2 N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists Human Necessities 3 Active
US9969738B2 N-acyl-(3-substituted)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders Human Necessities 2 Active
US10065961B2 Chiral N-acyl-5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof Emerging Cross-Sectional Technologies 2 Active
US9969745B2 N-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders Human Necessities 1 Active
US10683295B2 Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-A]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof Emerging Cross-Sectional Technologies 1 Active
US9695120B2 Substituted pyrrolidines as G-protein coupled receptor 43 agonists Chemistry; Metallurgy 1 Active
US10836768B2 N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists Chemistry; Metallurgy 1 Active
US10183948B2 N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists Chemistry; Metallurgy 1 Active
US10030025B2 Substituted [1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists Human Necessities 1 Active
US9770435B2 Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases Emerging Cross-Sectional Technologies 0 Active
US12162849B2 Synthesis of 3-methyl-1,2,4-thiadiazole-5-carbohydrazide or of the methyl-d3 deuterated form thereof Chemistry; Metallurgy 0 Active
US10544150B2 NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders Human Necessities 0 Active
US10624890B2 NK-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat Human Necessities 0 Active
US10941151B2 Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof Emerging Cross-Sectional Technologies 0 Active
US10214533B2 N-acyl-(3-substituted)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders Human Necessities 0 Active
US10065960B2 NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders Chemistry; Metallurgy 0 Active
US10017468B2 Substituted pyrrolidines as G-protein coupled receptor 43 agonists Chemistry; Metallurgy 0 Active
US11731974B2 N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists Chemistry; Metallurgy 0 Active
US11078203B2 Deuterated fezolinetant Chemistry; Metallurgy 0 Active
US9926325B2 NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders Human Necessities 0 Active
US11478472B2 NK-3 receptor antagonists for therapeutic treatment of leptin-related disease Human Necessities 0 Active
US10787458B2 Chiral synthesis of N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-A]pyrazines Chemistry; Metallurgy 0 Active

Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.